Teva Pharmaceutical Industries (TEVA) to Announce Quarterly Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is projected to announce its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of $0.08 per share and revenue of $4.0293 billion for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. On average, analysts expect Teva Pharmaceutical Industries to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $30.78 on Monday. Teva Pharmaceutical Industries has a one year low of $14.99 and a one year high of $37.35. The company has a market capitalization of $35.40 billion, a P/E ratio of 23.15, a P/E/G ratio of 3.25 and a beta of 0.86. The company’s 50-day simple moving average is $33.29 and its two-hundred day simple moving average is $32.69. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares in the company, valued at $2,825,792.40. This represents a 64.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the sale, the executive vice president directly owned 55,755 shares of the company’s stock, valued at $1,973,727. The trade was a 34.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 465,931 shares of company stock valued at $16,332,989 over the last ninety days. 0.54% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Wellington Management Group LLP grew its holdings in Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after purchasing an additional 6,878,304 shares during the last quarter. Schroder Investment Management Group raised its stake in shares of Teva Pharmaceutical Industries by 261.1% during the 4th quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after buying an additional 5,370,253 shares during the last quarter. ION Fund Management Ltd acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $126,400,000. Polar Capital Holdings Plc purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $80,983,000. Finally, Alyeska Investment Group L.P. boosted its position in shares of Teva Pharmaceutical Industries by 145.9% in the 3rd quarter. Alyeska Investment Group L.P. now owns 5,976,035 shares of the company’s stock worth $120,716,000 after buying an additional 3,545,577 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TEVA. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Friday, July 17th. Barclays raised their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Piper Sandler reissued an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Finally, Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.